Activity assessments in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 306-313

  Smolen, Josef S ^a,b   Aletaha, Daniel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; HUMAN; HYBRID AMERICAN COLLEGE OF RHEUMATOLOGY SCORE; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX;

ARTHRITIS, RHEUMATOID; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; VALIDATION STUDIES AS TOPIC;

EID: 41649120761     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282fbd382     Document Type: Review

References (55)

1. Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61:290-297.
2. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124:699-707.
3. Nell V, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43:906-914; Epub 2004 Apr 27.
4. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54:944-947.
5. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44:2009-2017.
6. Wells G, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition [abstract]. J Rheumatol 2005; 32:2016-2024.
7. van der Heijde DM, Van't Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51:177-181.
8. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles. J Rheumatol 1993; 20:561-565.
9. Scott DL, Panayi GS, van Riel PLCM, et al. Disease activity in rheumatoid arthritis -preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992; 10:521-525.
10. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729-740.
11. Boers M, Tugwell P, Felson DT, et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in RA clinical trials. J Rheumatol 1994; 21 (Suppl 41):86-89.
12. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, GC, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735.
13. Van der Heijde DMFM, van't Hof M, van Riel PL, van de Putte LBA. Development of a Disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993; 20:579-581.
14. van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatismresponse criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40.
15. Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-48.
16. vanGestel AM, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41:1845-1850.
17. Siegel JN, Zhen B-G. Use of the American College of Rheumatology N (ACRN) index of improvement in rheumatoid arthritis. Argument in Favor. Arthritis Rheum 2005; 52:1637-1641.
18. American College of Rheumatology Committee to Reevaluate Improvement Criteria.: A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007, 57:193-202. The study reports on the evaluation and performance of several dozen response measures in the context of their retrospective assessment in clinical trials and correlation with rheumatologists' opinion on improvement. The resulting hybrid ACR measure performed well in these analyses but is quite complex. It will have to be tested prospectively in future clinical trials against other less complex measures.
19. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982; 9:758-762.
20. Inoue E, Yamanaka H, Hara M, et al. Comparison of disease activity score (DAS)28: erythrocyte sedimentation rate and D. Ann Rheum Dis 2007; 66:407-409.
21. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625-2636.
22. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410-1413 originally published online 7 Jun 2005; doi:10.1136/ard.2005. 037333.
23. van der Heijde D, Klareskog L, Boers M, et al., TEMPO investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64:1582-1587.
24. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006; 65:637-641.
25. Aletaha D, Machold K, Nell VPK, Smolen JS. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Rheumatology 2006; 45: 1133-1139 [Epub ahead of print]
26. Aletaha D, Machold K, Nell VPK, Smolen JS. Rheumatoid arthritis core set measures and perception by rheumatologists. Arthritis Rheum 2005; 52 (Suppl).
27. Smolen JS, Breedveld FC, Schiff MH, et al. A Simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42:244-257.
28. Leeb BF, Andel I, Sautner J, et al. Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 2005; 53:56-60.
29. Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res 2005; 7:R796-R806.
30. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2007; 59:32-41. Although this was an open label study, the evaluation of remission as an endpoint makes this study particularly interesting. A significant proportion of patients attained this state within short term. Different remission rates were achieved with different instruments.
31. de Man YA, Hazes JM, van de Geijn FE, et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:716-722. Many patients with RA are in their child-bearing age and many therapies are contraindicated during pregnancy. The authors reveal that assessment of disease activity during pregancy may be confounded by changes accompanying pregnancy and suggest that, for example, scores employing CRP are preferable to those using ESR.
32. Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M. Which Variables Best Predict Change in Rheumatoid Arthritis Therapy in Daily Clinical Practice? J Rheumatol 2006; 33:1423-1426.
33. Wong AL, Harker JO, Park GS, Paulus HE. Longitudinal measurement of RA disease activity in a clinical practice setting: usefulness of the SDAI [abstract]. Arthritis Rheum 2004; 50 (Suppl):S386-S387.
34. Lissiane K, Guedes N, Kowalski SC, et al. The new indices Sdai and Cdai in early arthritis: similar performance to the Das28 index [abstract]. Arthritis Rheum 2006; 54 (Suppl):S206-S207.
35. Cuomo G, Molinaro G, La MG, et al. A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens. Reumatismo 2006; 58:22-25.
36. Gulfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis 2005; 64:1186-1189.
37. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 2006; 24 (Suppl 43):S045-S051.
38. Smolen J, van der Heijde D, Aletaha D, et al. A clinical score that does not require an acute phase response measure, the Clinical Disease Activity Index (CDAI), is of similar value as DAS and DAS28 as an indicator of low disease activity in rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54 (Suppl):S199.
39. Smolen J, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; in press
40. Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology 2007; 46:975-979. [Epub 2007 Mar 6]. The authors show that remission can be frequently achieved in clinical practice even with stringent instruments such as the SDAI and the CDAI. However, persistent remission is less frequent than remission on a cross-sectional basis.
41. Khanna D, Oh M, Furst DE, et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007; 57:440-447. In this study, different definitions of remission and low (or minimal) disease activity are used in a population of patients treated with nonbiological DMARDs. The authors reveal the differences in the proportions of patients attaining the respective states and point to the importance of clearly defining the instruments used in clinical trials. They also reveal the value of achieving low disease activity or remission with respect to good functional and radiographic outcomes.
42. Kapral T, Dernoschnig F, Machold KP, et al. Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther 2007; 9:R72.
43. Smolen JS, Han C, Bala M, et al. Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria [abstract]. Arthritis Rheum 2005.
44. Stamm TA, Aletaha D, Pflugbeil S, et al. The use of databases for quality assessment in rheumatoid arthritis. Clin Exp Rheumatol 2007; 25:82-85.
45. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005; 32:2410-2415.
46. Pincus T, Yazici Y, Bergman M, et al. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007; 21:789-804.
47. Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995; 38:795-798.
48. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263-269.
49. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005; 52:3381-3390.
50. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406-415. The BeSt trial has become a classic strategic trial employing treatment decisions upon tight control, which has significantly influenced current thinking. The two year data are presented here. While, as a consequence of the therapeutic strategies employed which involved biological agents at some time point in all populations, the different groups have achieved similar results at endpoint, patients who were started on intensive therapies fare particularly well.
51. Verstappen SM, Jacobs JW, van d V, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443-1449.
52. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56:3226-3235. Ttreatment response at 3-6 months from start of therapy is highly predictive of the response at endpoint (1 year), irrespective of the type of therapy. This indicates that therapies that are ineffective in terms of reaching low disease activity within 3-6 months should be discontinued and other treatment options employed.
53. Gossec L, Dougados M, Goupille P, et al. Combe B Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63:675-680.
54. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54:2784-2792.
55. Smolen JS, Sokka T, Pincus T. Breedveld FC A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 (5 Suppl 31):S209-S210.